Nicola Simon

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate–resistant Bcr-Abl kinases

Markus Warmuth, Nicola Simon, Olga Mitina et al. · Blood · 2002 · 135 citations · Full text

Medicine, Oncology, Pharmacology +12

Basement membrane components (matrigel) promote the tumorigenicity of human breast adenocarcinoma MCF7 cells and provide an in vivo model to assess the responsiveness of cells to estrogen

Agnès Noël, Nicola Simon, J. Raus et al. · Biochemical Pharmacology · 1992 · 48 citations

Medicine, Cell Biology, Oncology +12

Evaluation of in vitro reconstituted basement membrane assay to assess the invasiveness of tumor cells.

Nicola Simon, Agnès Noël, Jean‐Michel Foidart · PubMed · 1992 · 45 citations

Medicine, Cancer Biology, Cell Biology +16

The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate

Christine Schuster, Karin Forster, Henning Dierks et al. · Blood · 2002 · 43 citations · Full text

Life Sciences, Hematology, Molecular Biology +11

An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells

Matthias Peipp, Nicola Simon, Alexandra Loichinger et al. · Journal of Immunological Methods · 2001 · 29 citations · Full text

Pharmacy, Cell Biology, Immunology +13